RESEARCH PEPTIDE
Retatrutide 15 mg
Retatrutide 15 mg
Retatrutide is a single-molecule agonist studied across GIP, GLP-1, and glucagon receptors to examine integrated metabolic signalling.
Quality documentation
Certificate of Analysis Available
View the available testing documentation for Retatrutide 15 mg.
IDR 3.999.000
- Product
- Retatrutide
- Strength
- 15 mg
- Category
- Research Peptides
- Purity
- ≥99.6% PURITY
- Use
- Laboratory and scientific research only
- Price
- IDR 3.999.000
The power of triple-receptor metabolic research.
Retatrutide is a single-molecule agonist studied across GIP, GLP-1, and glucagon receptors to examine integrated metabolic signalling.
Research context
Preclinical pharmacology characterises retatrutide as a triple agonist across GIP, GLP-1, and glucagon receptors. Its research value lies in studying how these pathways interact across glucose, appetite, and energy-expenditure signalling without promising weight-loss or treatment outcomes.
Research interests
- Triple-receptor pharmacology
- Incretin and glucagon signalling
- Metabolic-pathway crosstalk
Explore further
Related research products
Research Peptides≥99.6% PURITY10 mg
AOD-9604 is a modified C-terminal growth-hormone fragment studied in preclinical lipid-metabolism, fat-oxidation, and adipose-signalling models.
≥99.6% PURITY
IDR 3.499.000
Research Peptides≥99.6% PURITY10 mg
BPC-157 is studied in preclinical models of tendon-fibroblast migration, FAK–paxillin activation, and tissue-repair signalling.
≥99.6% PURITY
IDR 1.199.000
Research Peptides≥99.6% PURITY5 mg
CJC-1295 is studied within growth hormone-releasing hormone research for its influence on GH and IGF-1 signalling.
≥99.6% PURITY
IDR 1.399.000
Research Peptides≥99.6% PURITY10 mg
DSIP is an exploratory neuropeptide studied at the intersection of slow-wave EEG activity, sleep signalling, and neuroendocrine regulation.
≥99.6% PURITY
IDR 2.199.000